5 trials tracked for achondroplasia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 21 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Treatment with BMN 111 demonstrated a statistically significant increase in Annualized Growth Velocity (AGV) from baseline at week 52 (p < 0.0001) 1. Additionally, patients receiving BMN 111 showed a statistically significant improvement in Height Z-score at week 52 (p < 0.0001) 1.
Clinical evaluations of body proportions using BMN 111 showed no statistically significant change in the Upper to Lower Segment Body Ratio at week 52 (p = 0.506) 1. Other assessments of body proportion ratios, including Arm Span to Height, Upper Arm Length to Forearm Length, and Thigh to Tibia length, did not show statistically significant changes from baseline 2.
Data regarding BMN 111 also indicated consistent results across different study cohorts for upper-to-lower body ratio measurements during the initial 6 months and throughout the full study period 4. Safety data for BMN 111 noted various treatment-emergent adverse events (TEAEs) across trial participants 2.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
